Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026
Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026
Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026
Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026
Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026
Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026
Company Drug

Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study

Fineline Cube Mar 29, 2023

China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced...

Company Deals

Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment

Fineline Cube Mar 29, 2023

Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based...

Company R&D

AstraZeneca Plans Tripled R&D Investment in China, Aims for 15 New Drugs by 2030

Fineline Cube Mar 29, 2023

At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the...

Company

Burning Rock Reports Q4 2022 Revenue Dip but 10.9% Full-Year Growth

Fineline Cube Mar 29, 2023

Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the...

Company Drug

CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments

Fineline Cube Mar 29, 2023

The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius...

Company Drug

Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment

Fineline Cube Mar 28, 2023

Brii Biosciences has announced a strategic decision to end the manufacturing and further development of...

Company Deals

Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening

Fineline Cube Mar 28, 2023

Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary...

Company

PharmaBlock Expands US Presence with New R&D Facility in West Chester

Fineline Cube Mar 28, 2023

PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a...

Company Drug

CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent

Fineline Cube Mar 28, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s...

Policy / Regulatory

NMPA Introduces Procedures to Adjust Chemical Generic Reference Preparations

Fineline Cube Mar 28, 2023

The National Medical Products Administration (NMPA) has released a document outlining procedures for the adjustment...

Company Deals

BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda

Fineline Cube Mar 28, 2023

Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...

Company Medical Device

Acotec Scientific’s Vericor Receives Marketing Approval from Thailand FDA

Fineline Cube Mar 28, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Drug

CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008

Fineline Cube Mar 28, 2023

Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a...

Company Drug

Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review

Fineline Cube Mar 28, 2023

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...

Company

Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs

Fineline Cube Mar 28, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022....

Policy / Regulatory

National ADR Monitoring Report Highlights Oncology Drugs and Elderly Patient Safety

Fineline Cube Mar 28, 2023

The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual...

Policy / Regulatory

China’s New Internet Advertising Regulations Impact Pharmaceutical Sector

Fineline Cube Mar 28, 2023

The State Administration for Market Regulation has released the latest version of the “Measures for...

Company

Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report

Fineline Cube Mar 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...

Company Drug

CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China

Fineline Cube Mar 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency...

Company Medical Device

Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China

Fineline Cube Mar 27, 2023

US-based medical device leader, Boston Scientific Corporation (NYSE: BSX), has announced the market launch of...

Posts pagination

1 … 498 499 500 … 619

Recent updates

  • Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows
  • Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
  • Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial
  • Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa
  • Marubeni Launches Xenleta in China After Complex Licensing Journey
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.